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Low birth weight increases neonatal morbidity and mortality, and surviving infants have increased risk of metabolic and
cardiovascular disturbances later in life, as well as other neurological, psychiatric, and immune complications. A gestational
excess of glucocorticoids (GCs) is a well-known cause for fetal growth retardation, but the biological basis for this association
remains elusive. Placental growth is closely related to fetal growth. The placenta is the main regulator of nutrient transport to
the fetus, resulting from the difference between placental nutrient uptake and the placenta’s own metabolism. The aim of this
study was to analyze how excess hydrocortisone affects placental glucose and lipid metabolism. Human placenta explants from
term physiological pregnancies were cultured for 18 hours under different hydrocortisone concentrations (2.75, 5.5, and 55mM;
1, 2, and 20mg/ml). Placental glucose and lipid uptake and the metabolic partitioning of fatty acids were quantified by isotopic
techniques, and expression of specific glucose transporterGLUT1was quantified bywestern blot. Cell viabilitywas assessed byMTT,
immunohistochemistry and caspase activity. We found that excess hydrocortisone impairs glucose uptake and lipoprotein lipase
(LPL) activity, coincident with a GC-dose dependent inhibition of fatty acid oxidation and esterification. None of the experimental
conditions showed an increased cell death. In conclusion, our results show that GC overexposure exerts a dysfunctional effect on
lipid transport and metabolism and glucose uptake in human placental explants. These findings could well be directly related to
a reduced placental growth and possibly to a reduced supply of nutrients to the fetus and the consequent fetal growth retardation
and metabolic programming.
1. Introduction
Low birth weight increases neonatal morbidity andmortality,
and surviving infants have higher risk of cardiovascular,
metabolic, neuroendocrine, and psychiatric disorders later
in life. These increased risks are hypothesized to be the
consequence of a fetal adaptive response to chronic nutrient
shortage during gestation, to ensure the development of
insulin independent organs such as central nervous system,
and may permanently affect adult health [1, 2].
Nutrient availability determines fetal growth [3]. The
placenta’s ability to supply nutrients to the fetus from the
mother depends on several factors such as maternal nutrition
status, uterine vascularization, placental size and morphol-
ogy, umbilical blood flow, the maternal-fetal concentration
gradient, the density and activity of placental specific nutrient
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transporters, and placental metabolism [4–6]. Placental dys-
function may restrict fetal growth by reducing fetal nutrient
supply, inducing intrauterine growth restriction (IUGR), and
fetal adaptive responses [7–9].
Placental weight, as a marker of the surface area available
for nutrient exchange, is a major determinant of fetal growth
and birth weight. A positive correlation between placental
and fetal weight at term has been well documented [10, 11].
Indeed, epidemiological studies suggest that placental weight
might be an independent marker of the long-term health
outcome of the fetus [12]. In general, low placental weight at
term is associated with lower neonatal weight and predicts
hypertension and coronary disease in offspring [13].
The placenta’s capacity for nutrient uptake for both, its
own metabolic needs and transport to the fetus, can be
affected by modifications in the number, density, and distri-
bution of nutrient-specific transporters [14–17]. Physiological
levels of glucocorticoids (GCs) are essential for embryo
implantation, fetal growth, tissue development, and matura-
tion of various organs to prepare the fetus for the extrauter-
ine life. However, supraphysiological levels of GCs are a
well-known cause of fetal growth retardation [18–22] and
long term consequences such as persistent hyperactivation
of hypothalamus-pituitary-adrenal axis, adult hypertension,
hyperglycaemia, and various neurodevelopment alterations
[23–25].
There is a clear relationship between elevated GC expo-
sure and placental growth restriction and functional modifi-
cations in various species including humans [26]. Although
it is known that placental growth restriction is related to the
type of GC, the dose, and the therapy duration and timing
[27], mechanisms by which GCs impact placental growth
remain elusive.
Interestingly, experimental data with ewes revealed that
while repeated maternal doses of corticosteroids result in
reduced placental and neonatal weights, their direct fetal
injection does not affect neither of them [28], suggesting
that GCs’ effects on neonatal weight are mediated by their
repercussion on placental development and function. Indeed,
the effects of GCs on placental cell cycle, apoptosis, placental
angiogenesis, and nutrient transporters have been extensively
studied in different in vitro and in vivo models [26, 29–
33]. However, little is known on how GCs (especially hydro-
cortisone) affect primarily placenta’s metabolism, and since
they exert key tissue-specific metabolic effects, we aimed in
this study to analyze specifically hydrocortisone’s impact on
placenta’s glucose and lipid metabolism.
2. Materials and Methods
2.1. Study Samples. Placentas were obtained from 9 women
with physiological, uneventful, full-term pregnancies, with
adequate birth weight newborns at the Obstetrics Depart-
ment of University Hospital Puerta del Mar in Ca´diz, Spain
(HUPM, Ca´diz) (Table 1). None of the mothers recruited
for this study had a history of chronic diseases, hyper-
tension, preeclampsia, infections, or fetal anomalies. All
women had uncomplicated singleton pregnancies, delivered
by programmed caesarean section without labor, and agreed
to participate in the study by written informed consent.
Placentas were collected within 10 minutes following
delivery. Each placenta was then weighed and sampled in
placental explants (∼100mg wet weight) from the villous
placenta region. Each explant was cultured in 24-well dishes
containing 2ml of culture medium per well (RPMI-1640 sup-
plemented with 5mM glucose, 10% FBS (v/v), 100 units/ml
penicillin G, and 100𝜇g/ml streptomycin) as described pre-
viously [34] and hydrocortisone (Actocortina, Nycomed
Pharma) at concentrations of 2.75, 5.5, and 55mM (1, 2, and
20mg/ml, respectively), for 18 hours. These hydrocortisone
concentrations were set after preliminary experiments on
cellular apoptosis and lipid metabolism with increasing
hydrocortisone concentrations. We finally set the experi-
ments with a range of doses from the minimal concentration
found to induce changes in lipid metabolism, to the highest
dose inducing such changes without inducing cell death, as a
positive control. Similarly, the timing for incubation was set
at 18 hours (theminimum to find changes in lipidmetabolism
in preliminary time-curve tests). Every experiment was
repeatedwith explants from4–6different placentas (n= 4–6).
The study was approved by the Research Ethics Com-
mittee of the Puerta del Mar University Hospital and the
Cadiz’s Bay-La JandaDistrict and performed according to the
Declaration of Helsinki.
2.2. Materials. Cell culture reagents (RPMI-1640 medium
without glucose and fetal bovine serum)were purchased from
Gibco, California, USA. The [9,10-3H]-palmitic acid, [3H]-
H
2
O, 2-[1,2-3H]-deoxy-D-glucose, [1-14C]-mannitol, and liq-
uid scintillation counting cocktail were from Perkin Elmer,
Massachusetts, USA. Hydrocortisone sodium phosphate,
as GC treatment used in this study, was purchased from
Nycomed Pharma (Zurich, Switzerland). Lipoprotein lipase
(LPL) was purchased from Sigma-Aldrich (St. Louis, USA).
MTT for the colorimetric assay for the nonradioactive quan-
tification of cellular metabolic activity was purchased from
Roche (Mannheim, Germany). Apoptosis in the placental
explants was analyzed by the Dead-End TM Fluorometric
TUNEL System Kit (Promega, Madison, WI, USA) and the
Caspase-GLO 3/7 Assay Kit (Promega, Madison, USA).
2.3. Glucose Transport Assay. Uptake of [3H]-2-DOG was
performed ex vivo in placental explants, as described previ-
ously [35], with the following modifications. Freshly isolated
placental explants were preincubated for 18 h in culture
medium in the presence or absence of GCs. Afterwards,
explants were washed in transport solution buffer (20mM
Hepes-Na pH 7.4, 140mMNaCl, 5mM KCl, 2.5mMMgSO
4
,
and 1M CaCl
2
) at room temperature and immediately trans-
ferred to transport solution plus 10 𝜇M2-DOG (18500Bq/mL
[3H]-2-DOG) and 39mM mannitol (11840 Bq/mL [14C]-
mannitol) with or without GCs for 1min. Explants were
then removed rapidly, rinsed with cold 0,9% NaCl to stop
reactions, blotted, digested in 1M NaOH, and analyzed for
14C and 3H content. Glucose transport was defined as nmol
of 2-DOG per mg of protein per minute.
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Table 1: Maternal, gestational, and newborns’ characteristics.
Parameter Value
Maternal Age (years) 35.22 ± 0.74
Gestational Age (weeks) 38.79 ± 0.41
Maternal Glucose (mg/dl) 86.89 ± 3.65
Maternal Total Cholesterol (mg/dl) 175.2 ± 6.12
Maternal HDL-Chol (mg/dl) 69.56 ± 0.99
Maternal Triglycerides (mg/dl) 67.00 ± 5.13
Placental weight (g) 584.0 ± 36.58
Newborn weight (g) 3351 ± 98.01
Newborn weight (percentile) 62.56 ± 5.99
Values are expressed as means ± SEM.
2.4. Western Blots for GLUT1, Cleaved Caspase 3, and Phos-
pho ERK Protein Levels. Mock and GCs-treated placental
explants were dissected and washed with ice-cold PBS,
followed by homogenization in lysis buffer (20mM Tris-
HCl pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1%
(v/v) Triton X-100, 2.5mM sodium pyrophosphate, 1mM
𝛽-glycerophosphate, 1mM Na
3
VO
4
, 1 𝜇g/ml leupeptin, and
1mM phenylmethylsulfonyl fluoride) and protease inhibitor
cocktail (Protease Inhibitor Cocktail, Sigma, St. Louis, MO).
After 10min. on ice, extracts were sonicated and centrifuged
at 18,000 X g for 10 minutes at 4∘C. Pellets were discarded
and solubilized proteins (60𝜇g/sample) were resolved by
10% SDS-PAGE and electrotransferred onto polyvinylidene
difluoride (PVDF) filters for immunoblotting by conven-
tional means. Membranes were blocked in 5% skimmed
milk at room temperature for 1 hour and then incubated
with primary antibody [glucose transporter 1 (Glut-1; 1:2000,
Abcam, Cambridge, UK), Cleaved Caspase 3 (Casp-3; 1:1000,
Cell Signaling, EEUU), (phospho-)p44/p42 MAP Kinase
Antibody (p-Erk1/p-Erk2 and Total Erk1/Erk2; 1:1000, Cell
Signaling, EEUU), and 𝛽-Actin (1:5000, Abcam, Cambridge,
UK)] in 5% BSA in PBS at 4∘C overnight. After washing off
excess primary antibody three times with PBS for 15 minutes,
membranes were then incubated with secondary antibody
(Anti-Rabbit Peroxidase; 1:2000, Sigma-Aldrich, EEUU).
Signals were detected by chemiluminescence (Immun-Start
western chemiluminescence kit, Bio-Rad, Madrid, Spain),
and band densitometry was quantified with the Image-J
software (NIH, USA).
2.5. RNA Isolation and Real-Time PCR. For Total RNA
isolation we used the RNAspin Mini Kit (GE Healthcare,
Buckinghamshire,UK). Reverse transcriptionwas performed
with the Transcriptor First Strand cDNA Synthesis Kit
(Roche, Mannheim, Germany) using 1𝜇g of RNA in 20 𝜇l of
reaction volume. The cDNA was diluted into 200 𝜇l for later
use in real-time PCR. Two primer pairs were used to amplify
the human target genes, GLUT-1 and GLUT-3: hGLUT1-
F, 5󸀠-GCGGAATTCAATGCTGATGAT-3󸀠; hGLUT1-R, 5󸀠-
CAGTTTCGAGAAGCCCATGAG-3󸀠 ; hGLUT3-F, 5󸀠-TTA-
TCTTCACCGGCTTCCTCA; hGLUT3-R, CAGCATTCA-
GAAGCGTCCTGGGTTC. 𝛽-Actin mRNA expression was
measured as housekeeping gene with the primers hBACT-
F, 5󸀠-TACCACTGGCATCGTGATGGACT-3󸀠; hBACT-R,
5󸀠-CGTCACACTTCATGATGGAG-3󸀠 . No significant dif-
ferences were detected in the 𝛽-actin mRNA expression
among the samples studied (data not shown). Real-time
PCR was carried out in 10𝜇l of reaction containing 5 𝜇l
of SensiFAST SYBR No-ROX Kit (Bioline, London, UK),
0.5𝜇l forward primer, 0.5𝜇l reverse primer, 3 𝜇l DEPC H
2
O,
and 1 𝜇l cDNA template. Following the initial denaturization
at 95∘C for 3min, 40 cycles of amplification were performed
with the following conditions: incubation at 95∘C for 15 s,
annealing at 60∘C for 20 s, and extension at 72∘C for 20 s.The
threshold cycles of each mRNA species were determined in
triplicate with the use of a Rotor-Gene 6000 System (Corbett,
Mortlake, Australia). The mRNA levels of the target genes
were expressed as relative folds over those of BACT that was
used as the internal reference.
2.6. Fatty AcidOxidation Assay. A stock of fatty acid solution
was prepared by conjugating palmitate with essentially fatty
acid-free bovine serum albumin (BSA) to generate a solution
of 25% (wt/vol) BSA, with 4mM palmitate for the culture
medium, as described previously [34]. Mitochondrial fatty
acid oxidation (FAO) assays were performed in placental
explants as previously described [34, 36]. Briefly, freshly
isolated explants were incubated in culture media in the
presence or absence of GCs, plus 1.25% BSA, 0.1mM cold
palmitate, and 18500 Bq/ml [3H]-palmitate at 37∘C for 18 h.
At the end of the incubation period, the medium was
collected and tritiated water determined by the vapor-phase
equilibration method of Hughes et al. [37]. FAO was defined
as nmol of palmitate per mg of tissue per hour.
2.7. Esterification into Total Lipids Assay. The esterification
rate in placental explants was determined as previously
described [34, 38]. Briefly, after similar incubation conditions
to those used for measurements of 𝛽-oxidation, in the
presence or absence of GCs, plus 0.1mM cold palmitate and
18500 Bq/mL [3H]-palmitate at 37∘ for 18 h., explants were
washed 3 times with 2mL of ice-cold PBS and homogenized
in 500𝜇L of PBS. An aliquot of 100 𝜇L was used to extract the
lipid content from samples according to Bligh and Dyer [39].
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Afterwards, the radioactive content was determined by liquid
scintillation counting. Esterification was defined as nmol of
palmitate per mg of tissue per hour.
2.8. LPL Activity Assay. Lipoprotein lipase (LPL) mediates
the hydrolysis of triglycerides from maternal lipoproteins to
obtain free fatty acids. It represents one potential mechanism
for increasing placental lipid transport.The LPL activity assay
kit is a fluorometric assay which includes a nonfluorescent
substrate emulsion that becomes intensely fluorescent upon
interaction with LPL.The fluorescence signal is proportional
to the LPL activity and can be monitored in a fluorome-
ter (𝜆ex=370 / 𝜆em=450nm) following the manufacturer’s
instructions. LPL activity was defined as nmol of label permg
of protein.
2.9. Cellular Metabolic Activity Assay. Cellular metabolic
activity of the explants after exposure to GCs was assessed by
MTT assay [40]. Placental explants were seeded in 24-well
dishes and the Cell Proliferation Kit I (Roche, Mannheim,
Germany) was used following the manufacturer’s instruc-
tions.
2.10. Assessment of Placental Apoptosis
2.10.1. TUNEL Assay. Apoptosis was assessed with a com-
mercially available fluorescent terminal deoxynucleotidyl
transferase biotin-dUTP nick end labeling (TUNEL) kit
(Dead-End TM Fluorometric TUNEL System Kit; Promega,
Madison, WI, USA). After being stained according to the
manufacturer’s instructions, the sections were mounted in
Vectashield with DAPI (Vector Laboratories, Vulingame, CA,
USA). Three explants from 6 different placentas were includ-
ed in each experimental condition; three sections per explant
were examined, analyzing 10 images from each section, to
determine the percentage of TUNEL-positive nuclei.
2.10.2. Caspase Glo Activity Assay. Placental explants lysates
were subjected to caspase 3/7 activities measurement with
Caspase-Glo 3/7 Assay Kit (Promega, Madison USA). 100𝜇l
of placental lysates (2𝜇g/𝜇l proteins) plus 100𝜇l of Caspase-
Glo reagent was added to each well and the content of the well
was gently mixed with a plate shaker at 300–500 rpm for 30
seconds. The plate was then incubated in darkness at room
temperature for 1 hour. The luminescence of each sample
was measured in a plate-reading luminometer (Thermo
Labsystems). Data of total caspase 3/7 activity in arbitrary
units (A.U.) were normalized to the mock sample and by
normalizing relative light units (rawdata) for the protein con-
tent of the lysate.
2.10.3. CleavedCaspase 3 Determination. Wemeasured levels
of cleaved caspase 3 by western blot as described above.
2.11. Statistical Analysis. Statistical analysis of data was per-
formed using the SPSS software and Graph Pad Prism 5.
The distributions were evaluated using histograms and the
Kolmogorov-Smirnov test and data were presented asmean ±
standard deviation. For quantitative variables, the descriptive
results were expressed by central and dispersion tendency
measures (mean, median, and standard deviation). The qual-
itative variables were expressed by means of frequencies and
percentages. Comparisons between more than two groups
were performed by Kruskal-Wallis nonparametric test fol-
lowed by Dunn’s test. Pairwise comparisons were performed
using Mann-Whitney U test with Bonferroni correction
(number of comparisons = 6). P<0.05 was considered for sta-
tistical significance.
3. Results
3.1. Hydrocortisone Decreases Glucose Uptake by Placental
Explants, in spite of Increased GLUT1 Protein Levels and
GLUT3 mRNA Expression. When cultured with 1mg/ml
(2.75mM) of hydrocortisone, there was no change in [3H]-
2-DOG uptake by explants. However, increasing concentra-
tions of GCs resulted in a ∼30-40% decrease in [3H]-2-DOG
uptake (p <0.05), with respect to 1mg/ml of GC and con-
trol (Figure 1(a)). To analyze if this decrease in glucose uptake
could be explained by a decrease in glucose transporters
expression or protein levels, we performed real-time PCR to
analyze GLUT1 and GLUT3 mRNA expression and quanti-
fied GLUT1 protein content by western blot. GC exposure
did not induce any significant change in GLUT1 mRNA
expression levels in any of the experimental GCs concentra-
tions (Figure 1(b)), but they increased GLUT3 expression at
2mg/ml (5.5mM) (Figure 1(c)), in a mirrored image of their
effect on glucose uptake. On the contrary, hydrocortisone
induced amild but significant increase inGLUT1 protein level
(p=0.007) (Figure 1(d)).
3.2. Placenta’s Fatty Acid Oxidation and Esterification Are
Decreased by Hydrocortisone in a Dose-Dependent Manner.
We determined the fatty acid oxidation (FAO) and the
fatty acid esterification (FAE) rates of the placental explants
cultured with GCs for 18 hours. FAO rate was reduced by ∼
25%, ∼50%, and ∼75% in placental explants treated with 2.75,
5.5, and 55mM (1, 2, and 20mg/ml), respectively (p=0.05;
p=0.008; p=0.01) (Figure 2(a)). Coinciding with reduced
FAO activity, FAE in the GC-treated group was also signif-
icantly lower compared with control (p<0.01) (Figure 2(b)).
Significant differences in FAE were detected already with
2.75mM (1mg/ml) of GCs.
3.3. LPL Activity Decreased in Placental Explants Treated with
Excess of Hydrocortisone. GCs induced a dose-dependent
inhibition of LPL activity in the explants after 18 hours
of incubation (Figure 3). GCs at 1mg/ml (2.75mM) did
not significantly affect LPL activity, but hydrocortisone at 2
and 20mg/ml (5.5 and 55mM) induced a ∼40% and ∼80%
decrease in LPL activity, respectively (p<0.01; p<0.001).
3.4. Hydrocortisone Decreases Cellular Metabolic Activity in
Placental Explants, While Apoptosis Markers Remain Unal-
tered. Cellular metabolic activity as measured by MTT assay
was decreased after incubation with hydrocortisone, and this
decrease became significant with a hydrocortisone concen-
tration of 20mg/ml (55mM) (Figure 4). To confirm if the
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Figure 1: Hydrocortisone’s eﬀects on glucose uptake and glucose transporters in placental explants. (a) Glucose uptake as measured by
[3H]-2-DOG incorporation. (b) GLUT1mRNA expression normalized by actinmRNA expression. (c) GLUT3mRNA expression normalized
by actinmRNA. (d) GLUT1 protein levels as measured by western blot, normalized by actin levels, together with a representative photograph.
Values are represented as means ± SEM for 5 independent experiments. ∗p<0.05; ∗∗p<0.025; ∗ ∗∗p<0.01 relative to control (A.U.: arbitrary
units).
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Figure 2: Hydrocortisone’s eﬀects in placental explants’ lipid metabolism. (a) Fatty acid oxidation, in nmol/hour/mg of protein, was
inhibited by glucocorticoids in a dose dependent manner. (b) Fatty acid esterification, in pmol/hour/mg of protein, was also decreased in a
dose dependent manner. Values are represented as means ± SEM for at least 5 independent experiments, in triplicate. ∗p≤0.05; ∗∗p≤0.01;
∗ ∗ ∗p≤0.001 relative to control.
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drocortisone concentrations.Valuesmeasured in nmol/mg of pro-
teins are represented as means ± SEM for at least 4 independent
experiments in triplicate. ∗p≤0.05; ∗∗p≤0.01; ∗ ∗ ∗p≤0.001 relative
to control.
decrease observed in metabolic activity could be explained
by apoptosis, three different apoptosismarkerswere analyzed,
TUNEL (by immunofluorescence microscopy), total cleaved
caspases 3 and 7 (by the Caspase Glo kit; Promega), and
finally cleaved caspase 3 (by western blot).
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Figure 4: Mitochondrial activity as measured by MTT. Absorb-
ance per mg of protein content, represented as means ± SEM for 6
independent experiments.∗p<0.05;∗∗p<0.025;∗∗∗p<0.01 relative
to control.
Firstly, a time-concentration curvewas carried out to ana-
lyze if apoptosis activation was triggered along the 18 hours of
the experimental process, being measured from 0-20mg/ml
hydrocortisone at 0, 1, 3, 6, and 18 hours of incubation. No
significant differences were detected in any of the apoptosis
markers along the experimental conditions assessed in the
time-concentration curve (results not shown). We found no
significant differences between the control condition and
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none of the GC concentration in density of TUNEL positive
cells (Figures 5(a) and 5(b)), caspase glo (Figure 5(c)), or
cleaved caspase 3 concentration (Figure 5(d)).
3.5. ERK Phosphorylation Is Decreased by Excess Hydrocorti-
sone. We found a dose-dependent decrease of ERK1,2 phos-
phorylation by GCs. While 1mg/ml (2.75mM) of hydrocor-
tisone did not significantly decrease ERK phosphorylation,
2mg/ml (5.5mM) induced a ∼25% decrease (p<0.001) and
20mg/ml (55mM) a ∼75% decrease (p<0.01) in phosphory-
lation (Figure 6).
4. Discussion
The placenta is a GC target organ expressing multiple GC
receptor isoforms [41]. GCs play a profound impact on
cellular metabolism, suppressing cellular glucose uptake, and
glycogen synthesis, and also reducing LPL activity together
with lipolysis promotion in peripheral tissues, while activat-
ing lipogenic pathways in central tissues, favoring peripheral
depletion with central depot [42].
We found that GCs excess induced an increase in
GLUT1 protein levels, in accordance with data from placental
endothelial cells (HPECs) [31, 32] and pregnant rats under
dexamethasone treatment [43]. GLUT1 is the only trans-
porter present as a functional protein in the syncytium near
term [44]; thus changes in its density and/or activity would
deeply influence placental and fetal development. Besides
the increase in GLUT1 protein levels, we did not find an
increase in its mRNA expression. This may be explained
by the finding that inhibitors of mitochondrial activity de-
crease GLUT1 transcript degradation [45], and we found,
accordingly, that excess hydrocortisone induced a decrease in
placental explants’ metabolic activity in our setting. Despite
the increase in its protein level, placental glucose uptake was
decreased, suggesting that the mechanism underlying this
effect may well be a GC-induced translocation of glucose
transporters from the plasmamembrane to intracellular sites,
as it is induced in fibroblasts and adipose tissue [46, 47]. The
glucose concentrations used in our model are unlikely the
cause for the changes observed in this glucose transporter,
since there is experimental evidence showing no changes in
GLUT1 levels or activity with glucose concentrations ranging
from 1 to 12mM of glucose [48]. As in the studies men-
tioned before, we also found an increase in GLUT3 mRNA
expression. In term placentas, GLUT3 is only expressed in
the endothelium of arterial sections of placental vasculature
[49, 50], and it has been speculated that an increase in its
levels may relate to low fetal glucose levels, in an attempt to
aid in glucose extraction frommaternal circulation [51]. Our
data supports that the GC induced decrease in glucose uptake
in our model promotes such placental adaptive response,
regardless of the fetal compartment.
Since glucose is the primary fuel required for placental
and fetal growth and development [5], when its uptake
is compromised, the placenta could alternatively use lipid
oxidation for energy generation. In our hands, term placental
explants failed to compensate the decreased glucose uptake
by increasing FAO.Moreover, excess hydrocortisone induced
a dose-dependent decrease in FAO in our model, as it has
been shown to be induced in other tissues [52]. This is in
accordance with our previous findings in a different model of
IUGR as it is the pregnancy complicated with preeclampsia
[53]. When the placenta decreases its FAO activity, it may
induce fatty acid esterification to increase lipid stores, as
we have shown in placentas from pregnancies complicated
with gestational diabetes [34, 54]. On the contrary, we found
that hydrocortisone induced a decrease in FAE activity. The
finding that placental explants cultured with GCs are not
using, or storing lipids, points to the possibility of a decreased
lipid uptake. Triglycerides need to be broken down to free
fatty acids by placental lipases such as lipoprotein lipase
(LPL), to be readily available for placental uptake [55, 56].
Indeed, GCs reduce LPL activity in peripheral fat depots [42];
hence this could be underlying the decreased placental lipid
metabolism we found with GCs. This finding, in accordance
with a previous report [57], contrasts with the increased in
LPL mRNA expression levels in placentas from severe IUGR
newborns with abnormal umbilical artery pulsatility index,
in what could be speculated to be an attempt to restore the
fuel availability to the fetus, although authors did notmeasure
LPL activity [58].
GCs are a well-known cause of cellular death by apoptosis
[59], and increased apoptosis has been reported in placentas
form other causes of IUGR such as preeclampsia and HELLP
syndrome [60]. Hence it was mandatory to check that the
decrease in placental explants metabolism induced by GCs
was not the result of an increased apoptosis, andwe tested this
by three different methods. We found no signs of increased
apoptosis with the hydrocortisone concentrations used nei-
ther by TUNEL, Caspase Glo assay, nor by cleaved caspase 3
levels, as it could be expected from the dose curve we per-
formed prior to the experiments to choose GCs concentra-
tions. Thus the decrease in MTT observed with the highest
concentration of hydrocortisone used could be explained by
the global energetic shortage leading to a decreasedmetabolic
activity of the placental explants, which would also be in
accordance with the decreased levels of phosphorylated Erk
found in response to GCs.
In summary, our data in placental explants suggest that
GCs excess disables human term placenta to regulate nutri-
ent transport, affecting primarily its efficiency for nutrient
uptake. It hinders placental glucose and lipid uptake inde-
pendently of the nutrient availability, showing the kind of
response to GCs expected from peripheral tissues.
The main limitation of the study which recommends a
cautious interpretation of the results is the high hydrocorti-
sone concentrations used. Studies on glucocorticoids’ effects
on placenta ex vivo are usually performed with dexametha-
sone or other synthetic corticoids. We intentionally used
hydrocortisone as an example of endogenous glucocorticoid;
thus we had to perform preliminary studies to set the hydro-
cortisone concentrations in our experiments. Interestingly,
we only found one article using hydrocortisone ex vivo in a
similar tissue (umbilical cord), and it was designed to test
the effects of different corticoids on fetal vasculature [61].
The range of hydrocortisone concentrations tested went from
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Figure 5: Assessment of hydrocortisone-induced cellular death by apoptosis in healthy-term placental explants. (a) Representative
microphotographs of TUNEL assay to determine apoptosis in each experimental condition; cells undergoing apoptosis present fluorescent
green nuclei. (b) Quantification of the % of TUNEL positive cells per condition. (c) Active caspases 3 and 7 as measured by luminometry,
using the Caspase Glo Assay. (d) Cleaved caspase 3 as determined by western blot and normalized by actin levels. Values are presented as
means ± SEM for 5 independent experiments. ∗p≤0.05; ∗∗p≤0.01; ∗ ∗ ∗p≤0.001 relative to control.
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Figure 6: Dose dependent inhibition of MAPK-signaling path-
way in placental explants by hydrocortisone.Western blot analysis
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pendent experiments. ∗p<0.05; ∗∗p<0.025; ∗ ∗ ∗p<0.010 relative
to control.
10−9 to 10−4M, and the relaxant effect of hydrocortisone on
the vasculature was dose dependent and peaked at the maxi-
mum concentration tested (10−4M). If the authors had tested
concentrations of 10−3M (in the range of the ones used in our
experiments), it is plausible to speculate on an even higher
effect, suggesting that the hydrocortisone concentrations
needed to exert effects in ex vivo models of placental tissue
could be much higher than physiological concentrations.
Similarly, the resulting concentrations we finally used are
relevantly higher than physiological cortisone concentrations
in vivo, but we previously proved that they did not induce cel-
lular apoptosiswhile inducing cellularmetabolism changes in
the placental explants, resembling well documented hydro-
cortisone metabolic effects on peripheral organs.
5. Conclusions
Excess hydrocortisone reduces human term placenta ex-
plants’ ability to uptake glucose and lipids, and their ability
to use these as energy source, inducing a cellular metabolic
arrest. This fuel shortage to the placenta may plausibly con-
tribute to a disrupted placental development and placental
insufficiency, leading to an inefficient nutrient transport to
the fetus. These findings suggest that growth restriction
of fetus from mothers needing corticoid therapy during
pregnancy is the result of fetal nutrient deprivation, besides
corticoids’ direct effect on the fetus. The fetal adaptive re-
sponses to this condition may result in developmental pro-
gramming of metabolism for fuel shortage favoring the
development of lifelong metabolic morbidities.
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